Silvija Kraljevic

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Masatoshi Kudo, Richard S. Finn, Shukui Qin et al. · The Lancet · 2018 · 5.4K citations · Full text

Medicine, Oncology, Pharmacology +12

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Masafumi Ikeda, Max W. Sung, Masatoshi Kudo et al. · Journal of Clinical Oncology · 2018 · 124 citations

Medicine, Oncology, Pharmacology +14

Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).

Ann‐Lii Cheng, Richard S. Finn, Shukui Qin et al. · Journal of Clinical Oncology · 2017 · 87 citations

Medicine, Oncology, Pharmacology +14

Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu, Sarah B. Goldberg, Xiuning Le et al. · Clinical Lung Cancer · 2021 · 72 citations · Full text

Medicine, Molecular Medicine, Oncology +14

1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Helena A. Yu, Helen Ambrose, Christina S. Baik et al. · Annals of Oncology · 2021 · 47 citations

Medicine, Oncology, Pharmacology +13